TetraGenetics Overview

  • Founded
  • 2004
Founded
  • Status
  • Private
  • Employees
  • 21
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $1.01M
Latest Deal Amount
  • Investors
  • 10

TetraGenetics General Information

Description

Developer of a bio-pharmaceutical platform designed to develop novel therapeutics for autoimmune diseases. The company's platform develops proprietary technology that helps in the rapid production of properly folded and functional ion channel proteins in membrane preparations for use in antibody discovery and small molecule screening programs, enabling physicians to obtain treatments for ion channel-related autoimmune diseases and pain management.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 91 Mystic Street
  • Arlington, MA 02474
  • United States
+1 (617) 000-0000

TetraGenetics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TetraGenetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Later Stage VC 29-Sep-2020 $1.01M 00.000 Completed Generating Revenue
16. Debt - PPP 28-Apr-2020 00.000 Completed Generating Revenue
15. Later Stage VC 19-Jul-2018 00000 00.000 Completed Generating Revenue
14. Later Stage VC 02-May-2017 00.00 00.000 Completed Generating Revenue
13. Grant 11-Jan-2016 00.000 00.000 Completed Generating Revenue
12. Later Stage VC 06-Mar-2015 000 00.000 Completed Generating Revenue
11. Later Stage VC 01-Jan-2014 00000 00.000 Completed Generating Revenue
10. Later Stage VC 21-May-2013 00000 00.000 Completed Generating Revenue
9. Grant 03-Apr-2013 $826K $3.37M Completed Generating Revenue
8. Later Stage VC 28-Aug-2012 $2.47M $3.37M Completed Generating Revenue
To view TetraGenetics’s complete valuation and funding history, request access »

TetraGenetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a bio-pharmaceutical platform designed to develop novel therapeutics for autoimmune diseases. The company's
Drug Discovery
Arlington, MA
21 As of 2021
00.000
0000000000 0 00.000

00000000

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000 000000000
San Francisco, CA
00 As of 0000
0000
0000000 0000 0000

0000 000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000000000000
Oxford, United Kingdom
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TetraGenetics Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prosetta Biosciences Private Equity-Backed San Francisco, CA 00 0000 0000000 0000 0000
0000 000000000000 Venture Capital-Backed Oxford, United Kingdom 000 00000 00000000000 00000
000000 Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 41 competitors. Get the full list »

TetraGenetics Executive Team (6)

Name Title Board Seat Contact Info
R. Douglas Kahn Chairman, President & Chief Executive Officer
Kevin O'Brien Chief Financial Officer
Theodore Clark Ph.D Founder, Chief Scientific Officer & Board Member
Paul Colussi Ph.D Senior Vice President, Research
You’re viewing 4 of 6 executive team members. Get the full list »

TetraGenetics Board Members (11)

Name Representing Role Since
Alison Taunton-Rigby Ph.D Self Board Member 000 0000
Christopher Taron Ph.D Self Board Member 000 0000
Daniel Grau Self Board Member 000 0000
Ellen Baron Ph.D Self Board Member 000 0000
Marc Cote Self Board Observer 000 0000
You’re viewing 5 of 11 board members. Get the full list »

TetraGenetics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TetraGenetics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Castile Ventures Venture Capital Minority 000 0000 000000 0
T1D Fund Venture Capital Minority 000 0000 000000 0
National Institute of General Medical Sciences Government 000 0000 000000 0
Boston Harbor Angels Angel Group Minority 000 0000 000000 0
NXT Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »